Controlled Ceasing of Colchicine Therapy in Familial Mediterranean Fever (FMF) Patients With Single MEFV (Mediterranean Fever) Gene Mutation

Launched by RAMBAM HEALTH CARE CAMPUS · Jun 25, 2014

Keywords

ClinConnect Summary

The diagnosis of FMF is mainly clinical and genetic tests are only used to confirm the diagnosis . Even though the disease is autosomal recessive, not all FMF patients have two recognizable MEFV mutations. The phenotype of FMF patients varies according to the genotype, as shown by a number of studies showing that patients with one MEFV mutation have milder disease or even no symptoms. Some of the previously mentioned studies have shown that ceasing colchicine prophylaxis in these patients caused no recurrence. So far, no prospective controlled study has tested the effect of colchicine cessa...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients diagnosed with FMF based on clinical criteria
• • FMF patients diagnosed of having at least one common MEFV mutation will be assigned to the study group. FMF patients who staid on colchicine treatment will be assigned to the control group, regardless of their genotype.
• • Patients who were on a continuous colchicine prophylactic treatment for six months prior to entering the study.
• • FMF patients who were free of acute FMF symptoms for six months prior to entering th study
• • Patients were included in the study only if they had normal serum level of SAA (up to 10 mg / l).
• Exclusion Criteria:
• • Patients that in the six months prior to entering the study continued to have classic FMF episodes despite being on a continuous prophylactic colchicine
• • Patients that had high level of SAA (above 10 mg/l) despite being on prophylactic colchicine treatment